Efficacy and Safety of the RewinD-LB Phase 2b Clinical Trial of Neflamapimod in Dementia With Lewy Bodies (DLB) (P8-3.002)
To obtain definitive clinical proof-of-concept for, i.e. demonstrate the efficacy of, the oral p38α kinase inhibitor neflamapimod as a treatment for dementia with Lewy bodies (DLB).
Authors
- Lawrence S. Honig (ORCID: https://orcid.org/0000-0002-9703-2265)
- Kelly Blackburn
- John J. Alam (ORCID: https://orcid.org/0000-0002-1285-1115)
- Niels D. Prins (ORCID: https://orcid.org/0000-0002-6297-7592)
- Stephen N. Gomperts (ORCID: https://orcid.org/0000-0002-0083-0077)
- Amanda E. Gardner
- James E. Galvin (ORCID: https://orcid.org/0000-0002-4561-0318)
- John‐Paul Taylor (ORCID: https://orcid.org/0000-0001-7958-6558)
Institutions
- University of Miami (US)
- Massachusetts General Hospital (US)
- Brain (Germany) (DE)
- Columbia College (CA)
- Royal College of Physicians (GB)
- Columbia University (US)
- Newcastle University (GB)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000211390
- Citations
- 1
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.47